Charles River Laboratories International (CRL) Current Deferred Revenue (2009 - 2026)

Charles River Laboratories International has reported Current Deferred Revenue for 18 years, with the latest figure at $203.0 million in Q2 2026.

• On a quarterly basis, Current Deferred Revenue fell 24.34% year-over-year to $203.0 million in Q2 2026; TTM through Jun 2026 was $203.0 million, a 24.34% decrease from a year earlier, with the FY2025 full-year figure at $256.0 million, down 9.54% from the prior year.
• Current Deferred Revenue was $203.0 million for Q2 2026 at Charles River Laboratories International, up from $194.3 million in the prior quarter.
• The five-year high for Current Deferred Revenue was $290.0 million in Q4 2022, with the low at $194.3 million in Q1 2026.
• Average Current Deferred Revenue over 5 years is $250.2 million, with a median of $251.7 million recorded in 2022.
• The sharpest annual moves came in 2022 and 2026: Current Deferred Revenue jumped 32.0% in 2022, then slipped 24.34% in 2026.
• Over 5 years, Current Deferred Revenue stood at $290.0 million in 2022, then retreated by 5.86% to $273.0 million in 2023, then increased by 3.66% to $283.0 million in 2024, then slipped by 9.54% to $256.0 million in 2025, then retreated by 20.69% to $203.0 million in 2026.
• The last three Current Deferred Revenue figures came in at $203.0 million (Q2 2026), $194.3 million (Q1 2026), and $256.0 million (Q4 2025), per Business Quant data.